TJ Biotech Holding ApS: Financial statements 2023
CVR: 41953616
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
TJ Biotech Holding ApS (CVR 41953616) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 70,004 and a net result of DKK -9,513,527 compared with DKK -215,772 the year before. That is an increase of 30.7% compared with the year before. Equity in the 2023 report amounted to DKK 13,754,831. The solvency ratio was 75.8%.
- Gross Profit
- DKK 70,004
- Profit/Loss
- DKK -9,513,527
- Equity
- DKK 13,754,831
- Total Assets
- DKK 18,140,481
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 70K | -9.5M | 13.8M | 0 |
| 2022 | - | 54K | -216K | 23.3M | 0 |
| 2021 | - | 1.7M | 413K | 23.5M | 1 |
| 2020 | - | 1.4M | 90K | 23.1M | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
TJ Biotech Holding ApS has published its annual report for 2022. Gross profit came to DKK 53,543, and the net result was DKK -215,772.
About TJ Biotech Holding ApS
TJ Biotech Holding ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2020. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of Thomas Engelbrecht Nordkild Jonassen. The company is owned by Thomas Engelbrecht Nordkild Jonassen. The company has 1 employee (2021). In 2025, the company reported a gross profit of DKK 70,424 and a net result of DKK 4,184,576 compared with DKK 667,738 the year before. Equity in the 2025 report amounted to DKK 18,607,145.
